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Abstract
Background: Asthma is generally accepted as an inflammatory disease that needs steroid treatment. However, when to start
with inhaled steroids remains unclear. A study was undertaken to determine when inhaled corticosteroids should be
introduced as the first treatment step. Objective: To investigate the effectiveness of early introduction of inhaled steroids on
decline in lung function in steroid-naı¨ve subjects with a rapid decline in lung function in general practice. Subjects: Patients
with signs/symptoms suspect of asthma (i.e., persistent and/or recurrent respiratory symptoms) and a decline in forced
expiratory volume in 1 s (FEV1) during 1-year monitoring of 0.080 l or more and reversible obstruction (]10%
predicted) or bronchial hyperresponsiveness (PC2058 mg/ml) were studied. They had been identified in a population
screening aiming to detect subjects at risk for chronic obstructive pulmonary disease (COPD) or asthma. Design: A
placebo-controlled, randomized, double-blind study. Methods: 75 subjects out of a random population of 1155 were found
eligible, and 45 were willingly to participate. Subjects were randomly treated with placebo or fluticasone propionate
250 mg b.i.d., and FEV1 and PC20 were monitored over a 2-year period. Outcome variables: The primary outcome measure
was decline in FEV1; the secondary outcome measure was bronchial hyperresponsiveness (PC20). Results: 22 subjects
were randomly allocated to the active group with inhaled corticosteroids and 23 to placebo. Change of FEV1 in the active
treated group was 43 ml in post-bronchodilator FEV1 (p0.341) and 62 ml/year (p0.237) in pre-bronchodilator
FEV1 after 1 year, and 22 ml (p0.304) for post-bronchodilator FEV1 and 9.4 ml (p0.691) for pre-bronchodilator
FEV1 after 2 years, compared to placebo. The effect on PC20 was almost one dose-step (p0.627) after 1 year and one
dose-step (p0.989) after 2 years.
Conclusion: In this study, the early introduction of inhaled corticosteroids in newly diagnosed asthmatic subjects with
rapid decline in lung function did not prove to be either clinically relevant or statistically significant in reversing the decline
in FEV1. For PC20, no significant changes were detected.
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Introduction
Asthma is considered a chronic inflammatory dis-
ease that requires anti-inflammatory treatment,
even in its earliest phase (1). Inhaled corticosteroids
are widely available for treatment, and withholding
steroids is assumed to result in irreversible lung
function decline (2). However, the efficacy of
inhaled corticosteroid treatment to modify this
decline in the early phase of the disease has never
been studied, and that was the objective of this
study. Subjects who had never in their life been
diagnosed with asthma or chronic obstructive pul-
monary disease (COPD) were recruited for this
study from the general population by means of
population screening, followed by repeated lung
function measurements to assess a rapid decline in
lung function and signs of bronchial hyperrespon-
siveness.
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Methods
Fluticasone 250 mg b.i.d. was tested in a 2-year
randomized, placebo-controlled study as part of
the DIMCA programme (3). This paper reports
the second part of this programme. Subjects were
invited to participate if a decline in forced expiratory
volume in 1 s (FEV1) of 0.080 l/year had been
established during an observation of 12 months as
well as the presence of 1) reversibility ]10%
predicted and/or 2) moderate bronchial hyperre-
sponsiveness (i.e., PC2058 mg/ml). Salbutamol
400 mg on demand was allowed as the only other
concomitant respiratory medication. Exacerbations
were treated with a fixed course of prednisolone and
antibiotics. Informed consent was obtained from all
subjects, and the local ethics committee approved
the study.
All lung function measurements were carried out
according to European Respiratory Society (4)
standards. The primary study endpoint was decline
in FEV1, and the secondary outcome measure was
bronchial hyperresponsiveness (PC20). The number
of evaluable patients needed was 36 per treatment
group (ß0.80, 0.05). Both an ‘‘intent to treat’’
analysis and an explanatory analysis were done.
Repeated measurement analyses were performed
using the SAS ‘‘PROC MIXED’’ procedure. All
tests were two tailed (pB0.05 was considered
statistically significant).
Results
Seventy-five subjects fulfilled the inclusion criteria, of
whom 37 showed a PC2058 mg/ml, 13 a reversibility
of ]10%, while 25 fulfilled both. Forty-five subjects
agreed to be included, 32 attended all scheduled
follow-up assessments and 13 dropped out (six from
the fluticasone group). There were no significant
differences between the control group and interven-
tion group, with the exceptions of FVC (3.9339
0.777 vs 4.21891.176), PC20 geometric mean (7.46 vs
5.86), pack years (7.7912.2 vs 9.0910.2) and
symptom score (0.590.82 vs 1.4491.39).
In Figure 1, the course of FEV1 (post- and pre-
bronchodilator) is shown. For the first year, a 43-ml
difference in FEV1 post (p0.341) and 62 ml (p
0.237) in FEV1 pre was demonstrated in favour of
fluticasone. After 2 years, the differences were 22 ml
(p0.304) and 9.4 ml (p0.691), respectively.
Analysis of PC20 showed a non-significant differ-
ence over the first year of almost one dose-step in
favour of fluticasone (p0.989). After 2 years, a
similar difference was found (p0.989). The ex-
planatory analysis did not reveal results in another
direction (Figure 2).
Discussion
This study investigated the efficacy of early steroid
treatment in subjects never in their life diagnosed by
Figure 1. Mean difference in FEV1 post from baseline for each point of measurement.
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a physician with asthma or COPD, with a rapid
decline in lung function and signs of bronchial
hyperresponsiveness. The study did not find that
fluticasone significantly slowed the decrease in FEV1
or decreased bronchial hyperresponsiveness over the
study period.
The study was able to reach the targeted number
of eligible subjects, but was underpowered, mainly
due to refusal to participate. Reasons for this were
unwillingness to get medication for (subjectively)
mild symptoms and fear of steroids. This in fact
hampers the effectiveness of any screening for early
asthma and COPD.
Other studies showed markedly beneficial effects
of early steroid intervention in steroid-naı¨ve patients
with asthma (1,5,6). However, these studies con-
cerned treatment of patients who had been diag-
nosed in regular care, and undertreatment might be
an explanation for the results found. This study was
unable to differentiate between asthma and COPD
as it was directed at their preclinical stage.
In conclusion, in this study, steroid-naı¨ve subjects
with a rapid decline in FEV1 did not benefit from
fluticasone 250 mg b.i.d. compared to a placebo
treatment, but the study remains inconclusive due to
being underpowered.
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Figure 2. Mean difference in PC20 from baseline for each point of measurement.
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